作者
Mark Litzow, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Charles Mullighan, Kathryn Roberts, Yanming Zhang, Janis Racevskis, Cheryl Willman, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Hillard Lazarus, Dan Arber, Brent Wood, Jacob Rowe, Keith Pratz, Shira Dinner, Noelle Frey, Steve Gore, Bhavana Bhatnagar, Ehab Atallah, Geoff Uy, Deepa Jeyakumar, Tara Lin, Shejal Patel, Michelle Elliott, Anjali Advani, Daniel Deangelo, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Richard Little, Harry Erba, Richard Stone, Selina Luger, Martin Tallman
发表日期
2023/8/1
期刊
HemaSphere
卷号
7
页码范围
e1944062
出版商
LWW
简介
Background: Patients (pts) with newly diagnosed acute lymphoblastic leukemia (ALL) often relapse even with achieving complete remission (CR) and minimal residual disease (MRD) negative (MRD-) status after chemotherapy (chemo). Blinatumomab (blin) is a bi-specific T cell engager molecule approved for relapsed/refractory ALL pts and pts MRD positive (MRD+)(> 0.1%) in 1st or 2nd CR. E1910 was a phase III trial randomizing pts age 30-70 yrs to chemo+/-blin to test whether blin improves outcomes in BCR: ABL-negative B-ALL. The study showed that in pts who were MRD-after induction, there was a significant improvement in overall survival (OS) in favor of the blin arm. These subgroup analyses describe outcomes in pts based on age (< or> 55 yr) and depth of MRD (undetectable vs between undetectable-0.01%).
Aims: Primary objective compared OS in MRD-pts who received chemo+/-blin. Subgroup …
学术搜索中的文章
M Litzow, Z Sun, R Mattison, E Paietta, C Mullighan… - HemaSphere, 2023